6ENT
 
 | | Structure of the rat RKIP variant delta143-146 | | 分子名称: | CHLORIDE ION, Phosphatidylethanolamine-binding protein 1, ZINC ION | | 著者 | Koelmel, W, Hirschbeck, M, Schindelin, H, Lorenz, K, Kisker, C. | | 登録日 | 2017-10-06 | | 公開日 | 2017-12-13 | | 最終更新日 | 2024-01-17 | | 実験手法 | X-RAY DIFFRACTION (2.66 Å) | | 主引用文献 | Conserved salt-bridge competition triggered by phosphorylation regulates the protein interactome.
Proc. Natl. Acad. Sci. U.S.A., 114, 2017
|
|
6ENS
 | | Structure of mouse wild-type RKIP | | 分子名称: | ACETATE ION, GLYCEROL, Phosphatidylethanolamine-binding protein 1 | | 著者 | Hirschbeck, M, Koelmel, W, Schindelin, H, Lorenz, K, Kisker, C. | | 登録日 | 2017-10-06 | | 公開日 | 2017-12-13 | | 最終更新日 | 2024-01-17 | | 実験手法 | X-RAY DIFFRACTION (1.3 Å) | | 主引用文献 | Conserved salt-bridge competition triggered by phosphorylation regulates the protein interactome.
Proc. Natl. Acad. Sci. U.S.A., 114, 2017
|
|
5NIQ
 | |
6GB1
 | |
6GDZ
 | | exendin-4 based dual GLP-1/glucagon receptor agonist | | 分子名称: | (2~{S})-2-[[(4~{S})-4-(hexadecanoylamino)-5-oxidanyl-5-oxidanylidene-pentanoyl]amino]pentanedioic acid, Exendin-4 | | 著者 | Evers, A, Kurz, M. | | 登録日 | 2018-04-25 | | 公開日 | 2018-06-20 | | 最終更新日 | 2019-05-08 | | 実験手法 | SOLUTION NMR | | 主引用文献 | Dual Glucagon-like Peptide 1 (GLP-1)/Glucagon Receptor Agonists Specifically Optimized for Multidose Formulations.
J. Med. Chem., 61, 2018
|
|
6GE2
 | | exendin-4 based dual GLP-1/glucagon receptor agonist | | 分子名称: | (2~{S})-2-[[(4~{S})-4-(hexadecanoylamino)-5-oxidanyl-5-oxidanylidene-pentanoyl]amino]pentanedioic acid, Exendin-4 | | 著者 | Evers, A, Kurz, M. | | 登録日 | 2018-04-25 | | 公開日 | 2018-06-20 | | 最終更新日 | 2019-05-08 | | 実験手法 | SOLUTION NMR | | 主引用文献 | Dual Glucagon-like Peptide 1 (GLP-1)/Glucagon Receptor Agonists Specifically Optimized for Multidose Formulations.
J. Med. Chem., 61, 2018
|
|
8F2A
 | | Human Amylin3 Receptor in complex with Gs and Pramlintide analogue peptide San385 (Cluster 5 conformation) | | 分子名称: | 2-acetamido-2-deoxy-beta-D-glucopyranose, Calcitonin receptor, Guanine nucleotide-binding protein G(I)/G(S)/G(O) subunit gamma-2, ... | | 著者 | Cao, J, Sexton, P.M, Wootten, D.L, Radostin, D. | | 登録日 | 2022-11-07 | | 公開日 | 2023-08-02 | | 最終更新日 | 2024-02-14 | | 実験手法 | ELECTRON MICROSCOPY (2.2 Å) | | 主引用文献 | Structural insight into selectivity of amylin and calcitonin receptor agonists.
Nat.Chem.Biol., 20, 2024
|
|
8F0K
 | | Human Amylin3 Receptor in complex with Gs and Pramlintide analogue peptide San385 | | 分子名称: | (2S)-2-{[(1R)-1-hydroxyhexadecyl]oxy}-3-{[(1R)-1-hydroxyoctadecyl]oxy}propyl 2-(trimethylammonio)ethyl phosphate, 2-acetamido-2-deoxy-beta-D-glucopyranose, CHOLESTEROL HEMISUCCINATE, ... | | 著者 | Cao, J, Sexton, P.M, Wootten, D.L. | | 登録日 | 2022-11-03 | | 公開日 | 2023-08-02 | | 最終更新日 | 2024-02-14 | | 実験手法 | ELECTRON MICROSCOPY (1.9 Å) | | 主引用文献 | Structural insight into selectivity of amylin and calcitonin receptor agonists.
Nat.Chem.Biol., 20, 2024
|
|
8F0J
 | | Calcitonin Receptor in complex with Gs and Pramlintide analogue peptide San45 | | 分子名称: | (2S)-2-{[(1R)-1-hydroxyhexadecyl]oxy}-3-{[(1R)-1-hydroxyoctadecyl]oxy}propyl 2-(trimethylammonio)ethyl phosphate, 2-acetamido-2-deoxy-beta-D-glucopyranose, CHOLESTEROL HEMISUCCINATE, ... | | 著者 | Cao, J, Sexton, P.M, Wootten, D.L, Belousoff, M.J. | | 登録日 | 2022-11-03 | | 公開日 | 2023-08-02 | | 最終更新日 | 2024-03-13 | | 実験手法 | ELECTRON MICROSCOPY (2 Å) | | 主引用文献 | Structural insight into selectivity of amylin and calcitonin receptor agonists.
Nat.Chem.Biol., 20, 2024
|
|
8F2B
 | | Amylin 3 Receptor in complex with Gs and Pramlintide analogue peptide San45 | | 分子名称: | (2S)-2-{[(1R)-1-hydroxyhexadecyl]oxy}-3-{[(1R)-1-hydroxyoctadecyl]oxy}propyl 2-(trimethylammonio)ethyl phosphate, 2-acetamido-2-deoxy-beta-D-glucopyranose, CHOLESTEROL HEMISUCCINATE, ... | | 著者 | Cao, J, Sexton, P.M, Wootten, D.L, Belousoff, M.J. | | 登録日 | 2022-11-07 | | 公開日 | 2023-08-02 | | 最終更新日 | 2024-03-13 | | 実験手法 | ELECTRON MICROSCOPY (2 Å) | | 主引用文献 | Structural insight into selectivity of amylin and calcitonin receptor agonists.
Nat.Chem.Biol., 20, 2024
|
|
